Columbia Laboratories to Present At the 2nd Annual Salomon Smith Barney Specialty Pharmaceuticals Conference.

Business Editors/Health & Medical Writers

LIVINGSTON, N.J.--(BUSINESS WIRE)--March 5, 2002

Columbia Laboratories (AMEX:COB) announced today that it will present at the 2nd Annual Salomon Smith Barney Specialty Pharmaceuticals Conference. The presentation will be made by Fred Wilkinson, Columbia's president and chief executive officer on March 7, 2002 at 4:30 p.m. EST (1:30 p.m. PST) at The Marriott East Side Hotel, New York.

This conference, including Columbia's presentation, will be simultaneously webcast and can be accessed by interested parties at: http://www.veracast.com/ssb/2002/specialty-pharmaceuticals/95218196.cfm. A replay of Columbia's presentation will be available by the end of the day of the presentation and for an additional 30 days thereafter, and may be accessed via the above URL.

Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to research and development of women's health care and endocrinology products, including those intended to treat infertility, dysmenorrhea, endometriosis and hormonal deficiencies. Columbia is also developing hormonal products for men and a buccal delivery system for peptides. Columbia's products primarily utilize the company's patented Bioadhesive Delivery System (BDS) technology.

This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management team. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, the timely and successful development of pharmaceutical products, competitive economic and regulatory factors in the pharmaceutical and health care industry, the outcome of pending litigation to which the company is a party, general economic conditions and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission.